- Home
- Publications
- Publication Search
- Publication Details
Title
Anticorps anti-CTLA-4
Authors
Keywords
-
Journal
M S-MEDECINE SCIENCES
Volume 27, Issue 10, Pages 850-858
Publisher
EDP Sciences
Online
2011-10-20
DOI
10.1051/medsci/20112710013
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- L’intrusion des régulateurs de l’épigénome mâle dans les cellules somatiques cancéreuses
- (2011) Sophie Rousseaux et al. M S-MEDECINE SCIENCES
- Le mot des coordinateurs
- (2011) Jean-Luc Teillaud et al. M S-MEDECINE SCIENCES
- Quand CRAF remplace BRAF dans le mélanome
- (2011) Nicolas Dumaz et al. M S-MEDECINE SCIENCES
- Immunothérapie des cancers
- (2011) Éric Tartour et al. M S-MEDECINE SCIENCES
- Rôle de CTLA-4 dans la cosignalisation négative du système immunitaire
- (2011) Daniel Olive et al. M S-MEDECINE SCIENCES
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic significance of autoimmunity during treatment of melanoma with interferon
- (2011) Michal T. Krauze et al. Seminars in Immunopathology
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- (2010) Geoffrey Y. Ku et al. CANCER
- Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
- (2010) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
- (2010) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
- (2010) A. A. Sarnaik et al. CLINICAL CANCER RESEARCH
- A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
- (2010) Evan M. Hersh et al. INVESTIGATIONAL NEW DRUGS
- Reply to E.M. Poeschl et al
- (2010) Christy L. Marshall et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Development of the Anti–CTLA-4 Antibody Tremelimumab
- (2010) Antoni Ribas SEMINARS IN ONCOLOGY
- Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
- (2009) Ji Luo et al. CELL
- Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
- (2009) A. Ribas et al. CLINICAL CANCER RESEARCH
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Gastrosplenic Fistula From Hodgkin's Lymphoma
- (2009) Carolyn D. Seib et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival for Stage IV Melanoma From an Unknown Primary Site
- (2009) Chris C. Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
- (2009) Luis H. Camacho et al. JOURNAL OF CLINICAL ONCOLOGY
- Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade
- (2009) Willemijn B. Breunis et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?
- (2008) C. Menard et al. CLINICAL CANCER RESEARCH
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- (2008) C. I. Liakou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS
- (2008) F Stephen Hodi et al. Nature clinical practice. Oncology
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started